Random-start ovarian stimulation in patients with cancer

Purpose of review Awaiting menses to start ovarian stimulation for oocyte/embryo cryopreservation in patients with cancer may result in a significant delay of cancer treatment that may lead to patients forgoing fertility preservation. The purpose of this review is to describe the new protocols to facilitate the start of ovarian stimulation, including random-start ovarian stimulation. Recent findings In random-start protocols, the number of total and mature oocytes retrieved, oocyte maturity rate, mature oocyte yield and fertilization rates are similar to those in conventional (early follicular phase start) protocols. Starting ovarian stimulation in the late follicular or luteal phase did not show any superiority against the other. The presence of corpus luteum or luteal phase progesterone levels did not adversely affect synchronized follicular development, number of mature oocytes retrieved, and/or fertilization rates. Summary Random-start ovarian stimulation provides a significant advantage by decreasing total time for the IVF cycle, and in emergent settings, ovarian stimulation can be started at a random cycle date for the purpose of fertility preservation without compromising oocyte yield and maturity.

[1]  YongLun Fu,et al.  Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). , 2014, Reproductive biomedicine online.

[2]  F. Martínez,et al.  Comparison of starting ovarian stimulation on day 2 versus day 15 of the menstrual cycle in the same oocyte donor and pregnancy rates among the corresponding recipients of vitrified oocytes. , 2014, Fertility and sterility.

[3]  M. Cedars,et al.  Random start controlled ovarian stimulation results in high oocyte developmental competence and embryo quality , 2014 .

[4]  S. Paluch-Shimon,et al.  Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. , 2014, Fertility and sterility.

[5]  U. Keskin,et al.  Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature. , 2014, JPMA. The Journal of the Pakistan Medical Association.

[6]  M. Cedars,et al.  A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders. , 2014, Fertility and sterility.

[7]  Yanping Li,et al.  Flexible ovarian stimulation in a poor responder: a case report and literature review. , 2013, Reproductive biomedicine online.

[8]  M. Sammel,et al.  Response to ovarian stimulation in patients facing gonadotoxic therapy. , 2013, Reproductive biomedicine online.

[9]  K. Oktay,et al.  Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. , 2012, Fertility and sterility.

[10]  G. Bates,et al.  Fertility preservation in women of reproductive age with cancer. , 2012, American journal of obstetrics and gynecology.

[11]  M. Cedars,et al.  Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. , 2012, Fertility and sterility.

[12]  L. Westphal,et al.  Oocyte cryopreservation as a fertility preservation measure for cancer patients. , 2011, Reproductive biomedicine online.

[13]  S. Nayak,et al.  Random-start gonadotropin-releasing hormone (GnRH) antagonist-treated cycles with GnRH agonist trigger for fertility preservation. , 2011, Fertility and sterility.

[14]  K. Oktay,et al.  Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. , 2011, Fertility and sterility.

[15]  K. Oktay,et al.  Fertility preservation in women with breast cancer. , 2010, Clinical obstetrics and gynecology.

[16]  G. Bedoschi,et al.  Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature , 2010, Journal of Assisted Reproduction and Genetics.

[17]  T. Strowitzki,et al.  Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. , 2009, Fertility and sterility.

[18]  K. Oktay,et al.  Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Oktay,et al.  Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. , 2007, Fertility and sterility.

[20]  H. Bang,et al.  Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. , 2006, The Journal of clinical endocrinology and metabolism.

[21]  Mitch Dowsett,et al.  Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.

[22]  A. Raziel,et al.  CLINICAL ASSISTED REPRODUCTION: Improvement of IVF Outcome in Poor Responders by Discontinuation of GnRH Analogue During the Gonadotropin Stimulation Phase—A Function of Improved Embryo Quality , 2001, Journal of Assisted Reproduction and Genetics.

[23]  R. Casper,et al.  Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. , 2001, Fertility and sterility.

[24]  D. Baird,et al.  Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment. , 1999, Human reproduction.

[25]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[26]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[27]  W. Hop,et al.  Growth patterns of nondominant ovarian follicles during the normal menstrual cycle. , 1990, Fertility and sterility.

[28]  A. Gougeon.  Dynamics of follicular growth in the human: a model from preliminary results. , 1986, Human reproduction.

[29]  S. Hillier,et al.  Follicular development during the luteal phase of the human menstrual cycle. , 1983, The Journal of clinical endocrinology and metabolism.

[30]  R. Frydman,et al.  Steroids and gonadotropins during the last pre-ovulatory phase of the menstrual cycle. Time relationships between plasma hormones levels and luteinizing hormone surge onset. , 1982, Journal of steroid biochemistry.

[31]  A. Pages,et al.  Mature oocyte cryopreservation: a guideline. , 2013, Fertility and sterility.

[32]  R. Pierson,et al.  Ovarian antral folliculogenesis during the human menstrual cycle: a review. , 2012, Human reproduction update.

[33]  A. Birmingham,et al.  The Practice Committee of the American Society for Reproductive Medicine and the Practice Committee of the Society for Assisted Reproductive Technology , 2006 .

[34]  P. Humaidan,et al.  Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. , 2005, Reproductive biomedicine online.

[35]  A. Birmingham.  Endometriosis and infertility The Practice Committee of the American Society for Reproductive Medicine , 2004 .

[36]  Z. Rosenwaks,et al.  Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. , 2003, Human Reproduction.